嵌合抗原受体（CAR）-T细胞疗法在治疗血液恶性肿瘤方面表现出显着疗效，目前已有9种CAR-T细胞产品上市。此外，CAR-T细胞已显示出将其治疗应用扩展到不同领域的巨大潜力，包括实体瘤、心肌纤维化、自身免疫性疾病和传染病。尽管取得了这些进展，与治疗相关的毒性反应和复发有关的重大挑战仍然存在。因此，当前的研究工作重点是解决这些问题，以提高 CAR-T 细胞的安全性和有效性并降低复发率。本文全面概述了 CAR-T 细胞疗法的现状，包括其成就、现有挑战和未来潜在的发展。版权所有 © 2023 作者。由威科健康公司代表中华医学会 (CMA) 和中国医学科学院血液学研究所发布

Chimeric antigen receptor (CAR)-T-cell therapies have exhibited remarkable efficacy in the treatment of hematologic malignancies, with 9 CAR-T-cell products currently available. Furthermore, CAR-T cells have shown promising potential for expanding their therapeutic applications to diverse areas, including solid tumors, myocardial fibrosis, and autoimmune and infectious diseases. Despite these advancements, significant challenges pertaining to treatment-related toxic reactions and relapses persist. Consequently, current research efforts are focused on addressing these issues to enhance the safety and efficacy of CAR-T cells and reduce the relapse rate. This article provides a comprehensive overview of the present state of CAR-T-cell therapies, including their achievements, existing challenges, and potential future developments.Copyright © 2023 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Medical Association (CMA) and Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College (IHCAMS).